metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus interferon alpha
	Ipilimumab (10 mg/kg) vs. interferon alpha	1	none	inconclusive results for: deaths (OS); RFS/DFS; AE (any grade); AE leading to death (grade 5)	suggested 44 % decrease in AE (grade 3-4) but the degree if certainty is unassessable	-
versus placebo
	Ipilimumab (10 mg/kg) vs. placebo	1	none	inconclusive results for: AE (any grade); TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); Colitis TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Endocrine disorders TRAE (grade 3-4) ; Gastrointestinal disorders TRAE (grade 3-4) ; Hepatobiliary disorders TRAE (grade 3-4) ; Hypophysitis TRAE (grade 3-4); Nervous system disorders TRAE (grade 3-4); Rash TRAE (grade 3-4); Skin and subcutaneous tissue disorders TRAE (grade 3-4) ; Colitis AE (grade 3-4); Hypophysitis AE (grade 3-4); Hypothyroidism AE (grade 3-4); Increase AST AE (grade 3-4); Increased ALT AE (grade 3-4)	statistically conclusive 28 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 27 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable statistically conclusive 24 % decrease in MFS but the degree if certainty is unassessable suggested 24 % decrease in MFS (extension) but the degree if certainty is unassessable suggested 25 % decrease in RFS (extension) but the degree if certainty is unassessable statistically conclusive 25 % decrease in RFS/DFS but the degree if certainty is unassessable suggested 89 % decrease in AE (grade 3-4) but the degree if certainty is unassessable suggested 96 % decrease in Abdominal pain AE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Cough AE (grade 3-4) but the degree if certainty is unassessable suggested 94 % decrease in Decreased appetite AE (grade 3-4) but the degree if certainty is unassessable suggested 74 % decrease in Diarrhoea AE (grade 3-4) but the degree if certainty is unassessable suggested 95 % decrease in Fatigue AE (grade 3-4) but the degree if certainty is unassessable suggested 96 % decrease in Headache AE (grade 3-4) but the degree if certainty is unassessable suggested 99 % decrease in Nausea AE (grade 3-4) but the degree if certainty is unassessable suggested 86 % decrease in Pruritus AE (grade 3-4) but the degree if certainty is unassessable suggested 79 % decrease in Pyrexia AE (grade 3-4) but the degree if certainty is unassessable suggested 94 % decrease in Rash AE (grade 3-4) but the degree if certainty is unassessable suggested 93 % decrease in Vomiting AE (grade 3-4) but the degree if certainty is unassessable suggested 98 % decrease in Weight decreased AE (grade 3-4) but the degree if certainty is unassessable	-
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus ipilimumab alone
	Ipilimumab (10 mg/kg) vs. ipilimumab alone	1	none	inconclusive results for: progression or deaths (PFS); DCR; DOR; objective responses (ORR); TRAE (any grade); TRAE (grade 3-4); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade); TRAE leading to discontinuation (grade 3-4); Adrenal insufficiency TRAE (grade 3-4); Colitis TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Endocrine disorders TRAE (grade 3-4) ; Eye disorders TRAE (grade 3-4); Febrile neutropenia TRAE (grade 3-4); Gastrointestinal disorders TRAE (grade 3-4) ; Guillain-Barré syndrome TRAE (grade 3-4); Hepatitis TRAE (grade 3-4); Hypersensitivity TRAE (grade 3-4); Hypophysitis TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Increase AST TRAE (grade 3-4); Increased ALT TRAE (grade 3-4); Increased lipase level TRAE (grade 3-4); Infusion-related reactions TRAE (grade 3-4); Maculopapular rash TRAE (grade 3-4); Nervous system disorders TRAE (grade 3-4); Pancreatitis TRAE (grade 3-4); Pancytopenia TRAE (grade 3-4); Pericarditis TRAE (grade 3-4); Peripheral neuropathy TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Polymyalgia Rheumatica TRAE (grade 3-4); Pruritic rash TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4); Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) ; Skin and subcutaneous tissue disorders TRAE (grade 3-4) ; Thyroiditis TRAE (grade 3-4); Uveitis TRAE (grade 3-4)	statistically conclusive 16 % decrease in deaths (OS) but the degree if certainty is unassessable	-
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant